Molecular Cancer Therapeutics: 19 (6)

Highlights

Highlights

Selected Articles from This Issue

Mol Cancer Ther June 1 2020 19 (6) 1219-1219;

Small Molecule Therapeutics

Small Molecule Therapeutics

Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality

Ying Xu, Qianqian Wang, Kunjie Xiao, Zhihao Liu, Lifeng Zhao, Xuejiao Song, Xi Hu, Zhanzhan Feng, Tiantao Gao, Weiqiong Zuo, Jun Zeng, Ningyu Wang and Luoting Yu

Mol Cancer Ther June 1 2020 19 (6) 1221-1231; DOI:10.1158/1535-7163.MCT-19-0578
Small Molecule Therapeutics

Type I IFN, Ly6C⁺ cells, and Phagocytes Support Suppression of Peritoneal Carcinomatosis Elicited by a TLR and CLR Agonist Combination

Allison M. Dyevoich and Karen M. Haas

Mol Cancer Ther June 1 2020 19 (6) 1232-1242; DOI:10.1158/1535-7163.MCT-19-0885
Small Molecule Therapeutics

A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate

Ozge Akbulut, Deniz Lengerli, Ozge Saatci, Elif Duman, Urartu O.S. Seker, Aynur Isik, Aytekin Akyol, Burcu Caliskan, Erden Banoglu and Ozgur Sahin

Mol Cancer Ther June 1 2020 19 (6) 1243-1254; DOI:10.1158/1535-7163.MCT-19-0957
Small Molecule Therapeutics

FGFR Inhibition Enhances Sensitivity to Radiation in Non–Small Cell Lung Cancer

Gopika SenthilKumar, Michael M. Fisher, Justin H. Skiba, Margot C. Miller, Sean R. Brennan, Saakshi Kaushik, Samantha T. Bradley, Colin A. Longhurst, Darya Buehler, Kwangok P. Nickel, Gopal Iyer, Randall J. Kimple and Andrew M. Baschnagel

Mol Cancer Ther June 1 2020 19 (6) 1255-1265; DOI:10.1158/1535-7163.MCT-19-0931
Small Molecule Therapeutics

Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo

Tianhong Pan, Mariane Martinez, Kelsea M. Hubka, Jian H. Song, Song-Chang Lin, Guoyu Yu, Yu-Chen Lee, Gary E. Gallick, Shi-Ming Tu, Daniel A. Harrington, Mary C. Farach-Carson, Sue-Hwa Lin and Robert L. Satcher

Mol Cancer Ther June 1 2020 19 (6) 1266-1278; DOI:10.1158/1535-7163.MCT-19-0174
Small Molecule Therapeutics

CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma

Ling Zeng, Anatoly Nikolaev, Chuan Xing, Deborah L. Della Manna and Eddy S. Yang

Mol Cancer Ther June 1 2020 19 (6) 1279-1288; DOI:10.1158/1535-7163.MCT-19-0946
Small Molecule Therapeutics

Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor

Alfonso García-Valverde, Jordi Rosell, Garazi Serna, Claudia Valverde, Joan Carles, Paolo Nuciforo, Jonathan A. Fletcher, Joaquín Arribas, Oliver Politz and César Serrano

Mol Cancer Ther June 1 2020 19 (6) 1289-1297; DOI:10.1158/1535-7163.MCT-19-1069

Large Molecule Therapeutics

Large Molecule Therapeutics

Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab

Beth Hutchins, Gary C. Starling, Mark A. McCoy, Danuta Herzyk, Frederique M. Poulet, John Dulos, Liming Liu, Soonmo Peter Kang, Laurence Fayadat-Dilman, Mark Hsieh, Christine L. Andrews, Gulesi Ayanoglu, Constance Cullen, Rene de Waal Malefyt, Robert A. Kastelein, Sabine Le Saux, Julie Lee, Sophie Li, Dan Malashock, Svetlana Sadekova, George Soder, Hans van Eenennaam, Aarron Willingham, Ying Yu, Michel Streuli, Gregory J. Carven and Andrea van Elsas

Mol Cancer Ther June 1 2020 19 (6) 1298-1307; DOI:10.1158/1535-7163.MCT-19-0774

Cancer Biology and Translational Studies

Cancer Biology and Translational Studies

Vitamin D Receptor Activation and Photodynamic Priming Enables Durable Low-dose Chemotherapy

Sriram Anbil, Michael Pigula, Huang-Chiao Huang, Srivalleesha Mallidi, Mans Broekgaarden, Yan Baglo, Pushpamali De Silva, Diane M. Simeone, Mari Mino-Kenudson, Edward V. Maytin, Imran Rizvi and Tayyaba Hasan

Mol Cancer Ther June 1 2020 19 (6) 1308-1319; DOI:10.1158/1535-7163.MCT-19-0791
Cancer Biology and Translational Studies

Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model

Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim and Toyohiro Hirai

Mol Cancer Ther June 1 2020 19 (6) 1320-1327; DOI:10.1158/1535-7163.MCT-19-0649
Cancer Biology and Translational Studies

Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR^Y1068 Phosphorylation

Caroline von Achenbach, Manuela Silginer, Vincent Blot, William A. Weiss and Michael Weller

Mol Cancer Ther June 1 2020 19 (6) 1328-1339; DOI:10.1158/1535-7163.MCT-19-0609
Cancer Biology and Translational Studies

Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2

Caroline Maloney, Michelle P. Kallis, Morris Edelman, Christopher Tzanavaris, Martin Lesser, Samuel Z. Soffer, Marc Symons and Bettie M. Steinberg

Mol Cancer Ther June 1 2020 19 (6) 1340-1350; DOI:10.1158/1535-7163.MCT-19-0903
Cancer Biology and Translational Studies

A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma

Nagendra K. Chaturvedi, Matthew J. Kling, Connor N. Griggs, Varun Kesherwani, Mamta Shukla, Erin M. McIntyre, Sutapa Ray, Yutong Liu, Timothy R. McGuire, J. Graham Sharp, Hamid Band, Shantaram S. Joshi and Don W. Coulter

Mol Cancer Ther June 1 2020 19 (6) 1351-1362; DOI:10.1158/1535-7163.MCT-19-0996
Cancer Biology and Translational Studies | AuthorChoice

Synthetic Lethality with Trifluridine/Tipiracil and Checkpoint Kinase 1 Inhibitor for Esophageal Squamous Cell Carcinoma

Shinya Ohashi, Osamu Kikuchi, Yukie Nakai, Tomomi Ida, Tomoki Saito, Yuki Kondo, Yoshihiro Yamamoto, Yosuke Mitani, Trang H. Nguyen Vu, Keita Fukuyama, Hiroshi Tsukihara, Norihiko Suzuki and Manabu Muto

Mol Cancer Ther June 1 2020 19 (6) 1363-1372; DOI:10.1158/1535-7163.MCT-19-0918
Cancer Biology and Translational Studies | AuthorChoice

An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer

Nancy A. Dawson, Matthew Zibelman, Timothy Lindsay, Rebecca A. Feldman, Michelle Saul, Zoran Gatalica, W. Michael Korn and Elisabeth I. Heath

Mol Cancer Ther June 1 2020 19 (6) 1373-1382; DOI:10.1158/1535-7163.MCT-19-0531

Main menu

User menu

Search

Table of Contents

Highlights

Small Molecule Therapeutics

Large Molecule Therapeutics

Cancer Biology and Translational Studies

Issue Highlights

Jump to

Articles

Info for

About MCT